Kymera Therapeutics (KYMR) Revenue (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Revenue data on file, last reported at $34.4 million in Q1 2026.

• On a quarterly basis, Revenue rose 55.5% year-over-year to $34.4 million in Q1 2026; TTM through Mar 2026 was $51.5 million, a 12.58% decrease from a year earlier, with the FY2025 full-year figure at $39.2 million, down 16.7% from the prior year.
• Revenue for Q1 2026 stood at $34.4 million, up from $2.9 million in the prior quarter.
• Over the last five years, Revenue for KYMR reached as high as $47.9 million in Q4 2023 and fell as low as $2.8 million in Q3 2025.
• Historically, Revenue has averaged $14.5 million across 5 years, with a median of $10.3 million in 2024.
• Across the five-year window, Revenue jumped 196.7% in 2023 and tumbled 84.56% in 2024, its largest moves.
• Year by year, Revenue stood at $16.1 million in 2022, then surged by 196.7% to $47.9 million in 2023, then tumbled by 84.56% to $7.4 million in 2024, then slumped by 61.18% to $2.9 million in 2025, then surged by 1097.39% to $34.4 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $34.4 million in Q1 2026, $2.9 million in Q4 2025, and $2.8 million in Q3 2025.